Applications of population approaches in toxicology

Toxicology Letters

Volumn 120, Issue 1-3, 2001, Pages 385-394

  Bois, Frédéric Y ^a  

^a INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

Author keywords

Bayes; Population models; Toxicodynamic models; Toxicokinetic models

Indexed keywords

BIOLOGICAL MARKER;

ANALYSIS; CONFERENCE PAPER; GENOTYPE; HUMAN; METHODOLOGY; POPULATION MODEL; POPULATION RESEARCH; PRIORITY JOURNAL; STATISTICS; TECHNIQUE; TOXICOKINETICS; TOXICOLOGY;

ANIMALS; BAYES THEOREM; BIOLOGICAL MARKERS; DEMOGRAPHY; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; TOXICOLOGY;

EID: 0035977843     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(01)00270-3     Document Type: Conference Paper

References (51)

1. Population pharmacokinetics
2. Optimum experimental designs for properties of a compartmental model
3. An introduction to the use of physiologically based pharmacokinetic models in risk assessment
4. The NONMEM system
5. Estimating population kinetics
6. Optimal statistical design for toxicokinetic studies
7. Analysis of PBPK models for risk characterization
8. PBPK model of trichloroethylene kinetics
9. PBPK model of trichloroethylene kinetics
10. Sensitivity analysis of a new model of carcinogenesis
11. Population toxicokinetics of tetrachloroethylene
12. Population toxicokinetics of benzene
13. Optimal design for a study of butadiene toxicokinetics in humans
14. Sparse sampling for assessment of drug exposure in toxicological studies
15. The impact of exercise and intersubject variability on dose estimates for dichloromethane derived from a physiologically based pharmacokinetic model
16. Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine
17. Variability in biological monitoring of organic solvent exposure - II. Application of a population physiological model
18. Pharmacokinetic modeling approaches for describing the uptake, systemic distribution, and disposition of inhaled chemicals
19. Markov chain Monte Carlo methods in biostatistics
20. Physiological pharmacokinetic analysis using population modelling and informative prior distributions
21. Reconstruction of short-term multi-route exposure to volatile organic compounds using physiologically based pharmacokinetic models
22. Development of new technique for risk assessment using physiologically based toxicokinetic models
23. Achieving credibility in risk assessment models
24. Markov chain Monte Carlo techniques for studying interoccasion and intersubject variability: Application to pharmacokinetic data
25. Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine
26. The diversity-stability debate
27. Bayesian design criteria: Computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model
28. A parallelogram approach for safety evaluation of ingested acetaldehyde
29. Bayesian optimal design in population models for haematologic data
30. 50 determination
31. A Bayesian approach to nonlinear random effects models
32. Population models
33. Understanding uncertainty
34. The population approach to pharmacokinetic data analysis: Rationale and standard data analysis methods
35. Population pharmacokinetics/dynamics
36. Calculation of the cumulative distribution function of the time to a small observable tumor
37. Estimation of occupational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin using a minimal physiologic toxicokinetic model
38. The use of population pharmacokinetics in drug development
39. An expected loss approach to the design of dosage regimens via sampling-based methods
40. The Bayesian analysis of population pharmacokinetic models
41. Bayesian analysis of linear and non-linear population models by using the Gibbs sampler
42. Structure and parameterization of pharmacokinetic models: Their impact on model predictions
43. Population pharmacokinetic/pharmacodynamic methodology and applications: A bibliography